Chinese biopharmaceutical Xie Chengrun: crossing the new pharmaceutical cycle with AI and internationalization

Economic Observer Follow 2026-09-05 21:18

Economic Observer reporter Zhang Ling

From 2015 to 2025 is the '10 years of innovation' for Chinese medicine, and 2026 can be seen as the beginning of a new cycle. "On September 5th, at the opening ceremony of the Yabuli Forum Summer Annual Meeting, Xie Chengrun, CEO of China Biopharmaceutical (01177. HK), Chairman of Zhengda Tianqing, and Chairman of Beijing Tede, said.

In the past 10 years, the number of innovative drugs approved for market in China has increased nearly 40 times; The number of clinical trials exceeds that of the United States, and by 2025, the total number of clinical trials will exceed 5000 for the first time, accounting for over 40% of the global total; The proportion of FIC (First in Class) drugs continues to increase. Compared to the previous cycle of "following and catching up", Xie Chengrun believes that China's pharmaceutical industry is transitioning to an "original leading" cycle, and a new growth logic is emerging - source innovation, global market, and technology driven.

In the 2026 Two Sessions, the government work report clearly listed biopharmaceuticals as an emerging pillar industry, and the policy support for innovative drugs continues to increase. In the first half of 2026, China will authorize 81 innovative drugs to foreign countries, with a total transaction amount of approximately 110 billion US dollars, accounting for 80% of the total for 2025; Approved 38 Class 1 innovative drugs for market launch; The number of new drugs under development accounts for about 30% of the world's total, ranking second in the world. China's pharmaceutical innovation efficiency has already ranked among the top in the world.

Xie Chengrun regards AI and internationalization as the two anchor points for China's biopharmaceutical industry to cross the cycle.

Currently, AI is bringing comprehensive disruption and reconstruction to various industries and fields. For the pharmaceutical industry, the cost of discovering and launching an innovative drug is about 2.6 billion US dollars, with a research and development cycle of up to ten years. The "Double Ten Law" is a huge challenge for every pharmaceutical company. But we are facing a window to break this law, "said Xie Chengrun.

Xie Chengrun mentioned a landmark event in the field of biomedicine recently: the successful Phase III clinical trial of a personalized mRNA cancer vaccine jointly developed by Moderna and Merck. After the news was announced, Moderna's stock price skyrocketed by 177% in one day, and its market value increased by $40 billion.

The excitement in the market lies not only in the fact that this is the first personalized new antigen therapy in human history to achieve positive results in Phase III clinical trials, but also in the fact that another protagonist of this breakthrough is AI. "Xie Chengrun said that Moderna's AI algorithm can process the genomic data of each patient in a short period of time, complete mutation assessment and target priority ranking, and output the final 34 new antigen combinations, directly guiding the molecular design of personalized vaccines. And, from sequencing to neoantigen prediction, from mRNA sequence design to final production, AI runs through the entire process. This marks a clear large-scale landing scenario for AI in the field of life sciences, and also validates the feasibility of AI driven drug discovery moving from concept to clinical practice.

Xie Chengrun introduced that in the past three years, China Biopharmaceutical has invested 600 million yuan in building AI capabilities, and has also cooperated with Huawei, ByteDance and other technology giants to incubate new AI pharmaceutical technologies; In addition, China Biopharmaceutical is an early investor in AI pharmaceutical companies such as Yingsi Intelligent (03696. HK), Jingtai Holdings (02228. HK), and Yitai Technology (07666. HK); In terms of research and development, AI assisted drug development in Chinese biopharmaceuticals has covered small molecules ADC、siRNA、OAPD、 Six major platforms, including molecular glue and TME, have empowered the development of 25 early-stage pipelines and 37 clinical stage pipelines, including the innovative COPD drug TQC3721 authorized to AstraZeneca for $1.9 billion in 2026; In the production field, Chinese biopharmaceuticals have utilized AI assisted production monitoring and prediction in the cell culture and purification stages of biopharmaceuticals, resulting in a 20% increase in antibody production and a 20% decrease in manufacturing costs.

So, AI is not a concept for Chinese biopharmaceuticals, it has already been realized as faster research and development speed, higher clinical value, lower manufacturing and sales costs, and better resource allocation. ”

Regarding internationalization, Xie Chengrun regards 2026 as the year of China's biopharmaceutical internationalization outbreak.

In 2026, China's biopharmaceutical industry achieved two external authorizations: in March, it authorized Rovacitinib to Sanofi, with a total transaction value of 1.53 billion US dollars, making it the largest authorization transaction in the domestic transplantation field; In July, we obtained overseas authorization for the innovative COPD drug TQC3721 from AstraZeneca, with a total value of 1.9 billion US dollars, making it the largest single product transaction in the respiratory field in the past three years.

In terms of introduction, Chinese biopharmaceuticals introduced from GlaxoSmithKline Bepirovirsen, the world's first innovative drug for functional cure of hepatitis B, which has been approved in Japan and is expected to be approved in China and the United States soon. In July 2026, Chinese biopharmaceuticals introduced two innovative drugs from GlaxoSmithKline's respiratory field, with global annual sales exceeding 4 billion pounds.

True internationalization is not only about selling products to overseas markets, but also embedding innovation capabilities into the global innovation network, "said Xie Chengrun. When the R&D system can simultaneously serve the clinical needs of China, the United States, Europe, and emerging markets, policy fluctuations, medical insurance adjustments, and intensified competition in a single market will not shake the company's foundation.

The reporter from the Big Health News Department focuses on major companies, doctors, important events, and figures in the field of health. Email: zhangling@eeo.